Screening for MASLD in patients with type 2 diabetes: is an early diagnosis a good diagnosis?
Currently, there is insufficient evidence to support the implementation of a MASLD screening program for patients with T2DM. Key evidence gaps remain, particularly regarding: (1) the natural history of MASLD in patients with T2DM; (2) optimal timing and utilization of novel anti-fibrotic therapies; and (3) the impact of screening on major adverse liver outcomes compared to targeted testing approaches.
Authors
- Ryan Buchanan (ORCID: https://orcid.org/0000-0003-0850-5575)
- Chinonso Nwoguh
- Tina Reinson (ORCID: https://orcid.org/0000-0002-2436-1906)
- Christopher D. Byrne (ORCID: https://orcid.org/0000-0001-6322-7753)
Institutions
- National Health Service (GB)
- University Hospital Southampton NHS Foundation Trust (GB)
- University of Southampton (GB)
Publication Details
- Journal
- Expert Review of Gastroenterology & Hepatology
- Published
- 2025-08-18
- DOI
- https://doi.org/10.1080/17474124.2025.2546597
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00